An erratic FDA is a threat to innovation

The article discusses how the erratic regulation and policymaking by the FDA, particularly concerning Moderna’s flu vaccine, threatens pharmaceutical innovation. It highlights the FDA’s initial refusal to review Moderna’s application, the subsequent intervention, and the negative impact on venture-capital investment in mRNA vaccines. The piece argues that such instability could deter large drug companies from risky innovations and prevent smaller biotechs from emerging, ultimately harming the public.